Navigation Links
The Quigley Corporation to Host Conference Call to Review Third Quarter Results and Provide Company Update
Date:11/11/2009

DOYLESTOWN, Pa., Nov. 11 /PRNewswire-FirstCall/ -- The Quigley Corporation, (Nasdaq: QGLY), www.quigleyco.com today announced it will host a conference call in which Ted Karkus, Chairman and CEO, will provide a Company overview including a review of activities, third quarter results and Q&A.

The conference call will be web cast live on The Quigley Corporation's web site, (www.quigleyco.com), at 11:00 AM (ET) on Thursday, November 12, 2009. The Company will issue its third quarter results at 8:30 AM (ET) that day.

Participants wishing to ask questions may access the live call by dialing (877) 217 - 6026. A replay of the conference call will be available for 30 days on the Company web site.

About The Quigley Corporation

The Quigley Corporation (Nasdaq: QGLY) (http://www.Quigleyco.com) is a diversified natural health medical science company. Its Cold Remedy segment is a leading marketer and manufacturer of the Cold-EEZE® family of lozenges and sugar free tablets clinically proven to significantly reduce the severity and duration of the common cold. Cold-EEZE® customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. The Quigley Corporation has several wholly owned subsidiaries including Quigley Manufacturing Inc., which consists of an FDA approved facility to manufacture Cold-EEZE® lozenges and fulfill other contract manufacturing opportunities, and Quigley Pharma, Inc., (http://www.QuigleyPharma.com), which conducts research in order to develop and commercialize a pipe
'/>"/>

SOURCE The Quigley Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. The Quigley Corporation Announces Sale of Its Health and Wellness Segment
2. The Quigley Corporation Reports Fourth Quarter & 2007 Annual Results; Increases Investment to $6.5 million in Pharmaceutical R&D in 2007
3. The Quigley Corporation Reports First Quarter 2008 Results - Increases Investment in Pharmaceutical R&D Future
4. The Quigley Corporation Names Gerard M. Gleeson to Succeed Retiring George J. Longo as Chief Financial Officer and Director
5. The Quigley Corporation Reports Third Quarter 2008 Results; Continues Investment in Pharmaceutical R&D Future
6. Quigley Announces Completion of Phase IIb Clinical Study of QR-333 For Diabetic Peripheral Neuropathy on November 25, 2008; Collection and Evaluation of Study Data to Begin Immediately Thereafter
7. The Quigley Corporation Reports Fourth Quarter and 2008 Annual Results; Continues To Invest In Pharmaceutical R&D Future
8. Unexpected Positive Finding Expands Potential for Quigley QR333 Drug for Diabetic Neuropathy; Findings Suggest Possible Disease Modification
9. The Quigley Corporation Reports First Quarter 2009 Results
10. The Quigley Corporation Issues Open Letter to Stockholders; Urges Stockholders to Reject Dissident Ted Karkus Solicitation Efforts
11. Quigley Corporation Receives Support from Leading Independent Proxy Advisory Firms; RiskMetrics and Glass Lewis Reject Dissident Stockholder Ted Karkus, Citing Failure to Provide Detailed Business Plan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... (PRWEB) August 28, 2014 Save ... Healthbox tech accelerator program in Tampa. Healthbox Florida ... innovative healthcare companies grow and achieve their goals. ... August 16th, at their launch event at the Mahaffey ... professionals. , Co-founder Matt Schneider commented on the Save ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 As September ... the more than 100 million people who suffer from ... from the Committee on Advancing Pain Research, Care, and ... of Health, is defined as any pain lasting more ... longer. And while chronic pain causes range from injury ...
(Date:8/28/2014)... 2014 ISI Telemanagement Solutions, Inc., ... be sponsoring the 2014 Presidio Exchange this September ... Presidio leadership to engage with the community with ... will be rolling out objectives for representatives to ... the event, ISI will be discussing their growing ...
(Date:8/28/2014)... CA (PRWEB) August 28, 2014 Commercial growers ... changing, new Kind K5 series LED grow lights, which perform ... Besides the wattage savings, Kind LED lighting needs no cooling ... room requires less cooling as well. Factoring in that they ... LED lighting is less than a year. , For many ...
(Date:8/28/2014)... 2014 Following the death of an 18-year-old ... FDA issued a warning on powdered caffeine products. ... substance that is readily available to consumers, despite the fact ... senior Logan Stiner died from an overdose of caffeine powder. ... the FDA to issue a safety advisory for caffeine powders. ...
Breaking Medicine News(10 mins):Health News:Save On Medical Accepted Into Healthbox Accelerator Program 2Health News:Interventional Pain Management Expert Glenn M. Lipton, M.D. Shares Common-Sense Tips for Preventing Chronic Pain 2Health News:Interventional Pain Management Expert Glenn M. Lipton, M.D. Shares Common-Sense Tips for Preventing Chronic Pain 3Health News:ISI Telemanagement Solutions, Inc. to Sponsor 2014 Presidio Exchange 2Health News:New Kind K5 Series LED Grow Lights Pave Way for Future of Indoor Gardening 2Health News:FDA Issues Safety Advisory for Caffeine Powders 2
... ... Legal Hold Pro™ service into doeDiscovery™. Further expanding doeLegal,s capabilities across the entire spectrum ... to offer increased value to all eDiscovery clients. , ... (PRWEB) May 14, 2010 -- doeLegal, ...
... at ethical issues arising from new neuroimaging research suggesting ... injury might be able to communicate. Title: Severe ... Andrew Billings, Larry R. Churchill, and Richard Payne, Summary: ... meaningful existence? The authors contend that "modern neuroscience ...
... ... in science , ... New York, NY (Vocus) May 13, 2010 -- Mount Sinai School of Medicine at ... of genetics and human genome research, and renowned humanists whose work has advanced biomedical ...
... ... for its many customers who have been touched by cancer, CIGNA expands access to all ... ... of access, quality and choice for its many customers who have been touched by cancer, ...
... 20 people over age 65, experts note, , THURSDAY, ... common irregular heartbeat known as atrial fibrillation in a ... and other forms of dementia, new research finds. , ... beat chaotically, causing blood to pool and increasing the ...
... blood test could spot those who need more supplementation, ... Seventy percent of pregnant women in the United States ... What,s more, the regimen of prenatal vitamins that many ... to boost levels when needed, researchers from the University ...
Cached Medicine News:Health News:doeLegal and Zapproved Sign Alliance to Add Legal Hold Pro to Suite of Powerful Online Legal Solutions 2Health News:doeLegal and Zapproved Sign Alliance to Add Legal Hold Pro to Suite of Powerful Online Legal Solutions 3Health News:The Hastings Center Report table of contents for May/June 2010 2Health News:The Hastings Center Report table of contents for May/June 2010 3Health News:Mount Sinai School of Medicine Commencement Honors Leaders in Genetics and Global Health 2Health News:Mount Sinai School of Medicine Commencement Honors Leaders in Genetics and Global Health 3Health News:Mount Sinai School of Medicine Commencement Honors Leaders in Genetics and Global Health 4Health News:Mount Sinai School of Medicine Commencement Honors Leaders in Genetics and Global Health 5Health News:Mount Sinai School of Medicine Commencement Honors Leaders in Genetics and Global Health 6Health News:CIGNA and Cancer Treatment Centers of America Reach New Agreement 2Health News:Treating Common Irregular Heartbeat Might Also Ward Off Alzheimer's 2Health News:Treating Common Irregular Heartbeat Might Also Ward Off Alzheimer's 3Health News:Many Pregnant Woman Not Getting Enough Vitamin D 2
(Date:8/28/2014)... Aug. 28, 2014 MGC Diagnostics Corporation (NasdaqCM: MGCD), ... call to discuss its financial results for the third ... call will be at 4:30 p.m. ET on Tuesday, ... for the third quarter of fiscal 2014 after the ... Participants can dial (877) 317-6789 or (412) 317-6789 ...
(Date:8/28/2014)... SAN ANTONIO , Aug. 28, 2014 ... therapeutics for the treatment of cancer, announces the recent ... the journal Steroids . The recent ... below), reviews the evolution and development of GenSpera,s prodrug technology ... activity of thapsigargin (from the plant Thapsia garganica ...
(Date:8/28/2014)... Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL ), ... evaluating the use of collagenase clostridium histolyticum (CCH) for treating ... a palpable cord will be presented at the upcoming 69 ... of the Hand (ASSH) being held in Boston ... is a biologic approved in the U.S., EU, ...
Breaking Medicine Technology:MGC Diagnostics Corporation to Report Third Quarter Fiscal 2014 Financial Results on Tuesday, September 9, 2014 2GenSpera Media Advisory; "Targeting thapsigargin towards tumors" Published in Steroids 2GenSpera Media Advisory; "Targeting thapsigargin towards tumors" Published in Steroids 3Auxilium Pharmaceuticals, Inc. To Present CCH Data For Concurrent Treatment Of Multiple Dupuytren's Cords At ASSH Annual Meeting 2Auxilium Pharmaceuticals, Inc. To Present CCH Data For Concurrent Treatment Of Multiple Dupuytren's Cords At ASSH Annual Meeting 3Auxilium Pharmaceuticals, Inc. To Present CCH Data For Concurrent Treatment Of Multiple Dupuytren's Cords At ASSH Annual Meeting 4Auxilium Pharmaceuticals, Inc. To Present CCH Data For Concurrent Treatment Of Multiple Dupuytren's Cords At ASSH Annual Meeting 5Auxilium Pharmaceuticals, Inc. To Present CCH Data For Concurrent Treatment Of Multiple Dupuytren's Cords At ASSH Annual Meeting 6
... New study finds patients who opt for surgery have decreased pain, ... with the spine disease called degenerative spondylolisthesis * ... pain over time compared to those who do not have surgery, ... The Journal of Bone and Joint Surgery ...
... GAITHERSBURG, Md., June 1 Overall survival data in ... GenVec,s ongoing Phase III Pancreatic Cancer Clinical Trial with ... Society of Clinical Oncology Annual Meeting in Orlando, FL. ... ) , , The poster ...
Cached Medicine Technology:Back to Normal: Surgery Improves Outcomes for Spine Patients 2Back to Normal: Surgery Improves Outcomes for Spine Patients 3Back to Normal: Surgery Improves Outcomes for Spine Patients 4TNFerade(TM) Phase III Data Presented at ASCO 2TNFerade(TM) Phase III Data Presented at ASCO 3